KBC Group’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.28M | Hold |
127,194
| – | – | 0.02% | 427 |
|
|
2026
Q1 | $7.18M | Sell |
127,194
-41,585
| -25% | -$2.42M | 0.02% | 399 |
|
|
2025
Q4 | $10M | Buy |
168,779
+15,362
| +10% | +$836K | 0.02% | 355 |
|
|
2025
Q3 | $8.31M | Buy |
153,417
+27,000
| +21% | +$1.54M | 0.02% | 382 |
|
|
2025
Q2 | $6.95M | Buy |
126,417
+1,117
| +0.9% | +$65.8K | 0.02% | 405 |
|
|
2025
Q1 | $8.86M | Sell |
125,300
-5,398
| -4% | -$363K | 0.03% | 370 |
|
|
2024
Q4 | $8.59M | Sell |
130,698
-33,249
| -20% | -$2.23M | 0.02% | 412 |
|
|
2024
Q3 | $11.5M | Sell |
163,947
-68,308
| -29% | -$5.71M | 0.03% | 354 |
|
|
2024
Q2 | $19.1M | Buy |
232,255
+2,264
| +1% | +$188K | 0.06% | 250 |
|
|
2024
Q1 | $20.1M | Sell |
229,991
-12,109
| -5% | -$1.08M | 0.06% | 245 |
|
|
2023
Q4 | $23.3M | Sell |
242,100
-7,922
| -3% | -$701K | 0.08% | 235 |
|
|
2023
Q3 | $22.1M | Sell |
250,022
-37,208
| -13% | -$3.31M | 0.09% | 226 |
|
|
2023
Q2 | $24.9M | Buy |
287,230
+7,566
| +3% | +$712K | 0.1% | 189 |
|
|
2023
Q1 | $27.2M | Sell |
279,664
-42,036
| -13% | -$4.36M | 0.12% | 174 |
|
|
2022
Q4 | $33.3M | Buy |
321,700
+94,560
| +42% | +$8.88M | 0.16% | 146 |
|
|
2022
Q3 | $19.3M | Sell |
227,140
-700
| -0.3% | -$62.3K | 0.1% | 208 |
|
|
2022
Q2 | $18.9M | Buy |
227,840
+43,486
| +24% | +$3.46M | 0.09% | 232 |
|
|
2022
Q1 | $14.2M | Sell |
184,354
-8,151
| -4% | -$682K | 0.06% | 284 |
|
|
2021
Q4 | $17M | Sell |
192,505
-135,059
| -41% | -$11.1M | 0.06% | 280 |
|
|
2021
Q3 | $25.3M | Buy |
327,564
+93,826
| +40% | +$7.4M | 0.09% | 222 |
|
|
2021
Q2 | $19.5M | Buy |
233,738
+49,110
| +27% | +$3.89M | 0.07% | 266 |
|
|
2021
Q1 | $13.9M | Buy |
184,628
+40,507
| +28% | +$3.31M | 0.06% | 317 |
|
|
2020
Q4 | $12.6M | Sell |
144,121
-56,718
| -28% | -$4.5M | 0.06% | 297 |
|
|
2020
Q3 | $15.3M | Buy |
200,839
+10,052
| +5% | +$1.02M | 0.09% | 221 |
|
|
2020
Q2 | $23.5M | Buy |
190,787
+93,483
| +96% | +$9.29M | 0.16% | 147 |
|
|
2020
Q1 | $8.22M | Sell |
97,304
-62,427
| -39% | -$5.38M | 0.07% | 276 |
|
|
2019
Q4 | $13.5M | Buy |
159,731
+12,695
| +9% | +$959K | 0.09% | 266 |
|
|
2019
Q3 | $9.91M | Buy |
147,036
+27,083
| +23% | +$2.09M | 0.07% | 313 |
|
|
2019
Q2 | $10.3M | Buy |
119,953
+16,852
| +16% | +$1.44M | 0.08% | 294 |
|
|
2019
Q1 | $9.16M | Sell |
103,101
-4,402
| -4% | -$408K | 0.08% | 313 |
|
|
2018
Q4 | $9.15M | Sell |
107,503
-34,780
| -24% | -$3.31M | 0.1% | 247 |
|
|
2018
Q3 | $13.8M | Buy |
142,283
+101,089
| +245% | +$10.1M | 0.1% | 236 |
|
|
2018
Q2 | $3.88M | Sell |
41,194
-233,204
| -85% | -$20.4M | 0.03% | 456 |
|
|
2018
Q1 | $22.2M | Sell |
274,398
-39,873
| -13% | -$3.42M | 0.21% | 122 |
|
|
2017
Q4 | $28M | Sell |
314,271
-52,601
| -14% | -$4.57M | 0.24% | 110 |
|
|
2017
Q3 | $34.1M | Buy |
366,872
+29,264
| +9% | +$2.59M | 0.31% | 79 |
|
|
2017
Q2 | $30.7M | Buy |
337,608
+52,847
| +19% | +$4.81M | 0.3% | 89 |
|
|
2017
Q1 | $25M | Buy |
284,761
+109,033
| +62% | +$9.7M | 0.23% | 108 |
|
|
2016
Q4 | $14.6M | Buy |
175,728
+88,857
| +102% | +$7.64M | 0.14% | 172 |
|
|
2016
Q3 | $8.04M | Buy |
86,871
+45,963
| +112% | +$4.33M | 0.09% | 246 |
|
|
2016
Q2 | $3.18M | Buy |
40,908
+2,046
| +5% | +$174K | 0.05% | 422 |
|
|
2016
Q1 | $3.21M | Buy |
38,862
+19,407
| +100% | +$1.58M | 0.05% | 389 |
|
|
2015
Q4 | $2.04M | Sell |
19,455
-9,749
| -33% | -$1.02M | 0.04% | 468 |
|
|
2015
Q3 | $3.08M | Sell |
29,204
-47,215
| -62% | -$6.31M | 0.06% | 339 |
|
|
2015
Q2 | $10.5M | Buy |
76,419
+19,865
| +35% | +$2.46M | 0.13% | 195 |
|
|
2015
Q1 | $7.05M | Buy |
56,554
+10,473
| +23% | +$1.11M | 0.09% | 253 |
|
|
2014
Q4 | $4.17M | Buy |
46,081
+38,977
| +549% | +$3.24M | 0.05% | 396 |
|
|
2014
Q3 | $512K | Sell |
7,104
-5,282
| -43% | -$347K | 0.02% | 742 |
|
|
2014
Q2 | $771K | Sell |
12,386
-35,221
| -74% | -$2.13M | 0.01% | 805 |
|
|
2014
Q1 | $3.25M | Sell |
47,607
-46,026
| -49% | -$3.39M | 0.05% | 387 |
|
|
2013
Q4 | $6.59M | Buy |
93,633
+23,388
| +33% | +$1.59M | 0.1% | 261 |
|
|
2013
Q3 | $5.07M | Buy |
70,245
+11,349
| +19% | +$754K | 0.08% | 305 |
|
|
2013
Q2 | $3.28M | Buy |
+58,896
| New | +$3.67M | 0.06% | 374 |
|
Other funds holding BMRN
VPC
KBC Group's BMRN Position: Q2 2026 in Review
KBC Group held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 127,194 shares worth $7.28M. The position accounts for 0.02% of the portfolio, ranked #427.
KBC Group first reported a position in BMRN in Q2 2013 and has held it in 53 quarters since. The position peaked at $34.1M in Q3 2017. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.
- KBC Group held 127,194 shares of BioMarin Pharmaceuticals worth $7.28M as of Q2 2026.
- KBC Group left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
- BioMarin Pharmaceuticals made up 0.02% of KBC Group's portfolio in Q2 2026, its #427 holding.
- KBC Group first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- KBC Group's BioMarin Pharmaceuticals position peaked at $34.1M in Q3 2017.
- 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.
Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.